Simplex Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Simplex Trading’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.3K	Sell	3,075 -25,897	-89%	-$429K	﹤0.01%	5719
2025 Q4	$382K	Sell	28,972 -29,257	-50%	-$345K	﹤0.01%	3573
2025 Q3	$417K	Buy	+58,229	New	+$3.03M	﹤0.01%	4056
2024 Q3	–	Sell	-2,118	Closed	-$99.3K	–	9148
2024 Q2	$93K	Buy	+2,118	New	+$89.7K	﹤0.01%	5448
2024 Q1	–	Sell	-35,179	Closed	-$1.91M	–	9450
2023 Q4	$2.12M	Buy	+35,179	New	+$1.81M	﹤0.01%	2304

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading's MLTX Position: Q1 2026 in Review

Simplex Trading reduced its MoonLake Immunotherapeutics (MLTX) stake by 89% in Q1 2026, selling an estimated $429K and leaving 3,075 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5719.

Simplex Trading first reported a position in MLTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $2.12M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Simplex Trading held 3,075 shares of MoonLake Immunotherapeutics worth $57.3K as of Q1 2026.
Simplex Trading sold 25,897 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $429K.
MoonLake Immunotherapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #5719 holding.
Simplex Trading first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 5 quarters since.
Simplex Trading's MoonLake Immunotherapeutics position peaked at $2.12M in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.